Eli Lilly and Company (NYSE:LLY) Earns Outperform Rating from Analysts at Sanford C. Bernstein

Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company (NYSE:LLY) in a research note published on Thursday morning, Marketbeat reports. The firm issued an outperform rating and a $1,100.00 target price on the stock.

LLY has been the subject of several other reports. Guggenheim increased their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Citigroup started coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Barclays increased their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $986.00.

Eli Lilly and Company Stock Up 0.1 %

Shares of LLY stock opened at $917.97 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock has a market cap of $872.44 billion, a P/E ratio of 135.19, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a 50 day simple moving average of $921.21 and a two-hundred day simple moving average of $858.02.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. On average, research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $32,000. LGT Financial Advisors LLC purchased a new stake in Eli Lilly and Company during the second quarter worth $36,000. Redmont Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at $40,000. Morton Brown Family Wealth LLC raised its position in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC lifted its stake in shares of Eli Lilly and Company by 53.3% during the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after purchasing an additional 16 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.